NexgenRx Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

NexgenRx hat ein Gesamteigenkapital von CA$8.3M und eine Gesamtverschuldung von CA$0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CA$29.3M bzw. CA$21.0M. NexgenRx Das EBIT des Unternehmens beträgt CA$122.9K, so dass der Zinsdeckungsgrad 4.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CA$1.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

CA$0

Verschuldung

Zinsdeckungsgrad	4.2x
Bargeld	CA$1.36m
Eigenkapital	CA$8.27m
Gesamtverbindlichkeiten	CA$21.01m
Gesamtvermögen	CA$29.29m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NXGDie kurzfristigen Aktiva des Unternehmens (CA$22.7M) übersteigen seine kurzfristigen Passiva (CA$20.6M).

Langfristige Verbindlichkeiten: NXGDie kurzfristigen Vermögenswerte des Unternehmens (CA$22.7M) übersteigen seine langfristigen Verbindlichkeiten (CA$386.8K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NXG ist schuldenfrei.

Schulden abbauen: NXG hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 163.1% betrug.

Schuldendeckung: NXG hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: NXG hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

NexgenRx Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen